source
- Vir hepatitis D drug succeeds in first pivotal studyA program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.BioPharma Dive · 18h ago↗ source
- Vir Biotechnology reports positive results for hepatitis D combo in first pivotal trialVir Biotechnology announced that its chronic hepatitis D treatment met its primary goal in the first of three late‑stage studies. The trial evaluated a once‑monthly combination therapy that include…